Medigen Biotechnology (3176) — Cash Flow Reinvestment Rate
Medigen Biotechnology (3176) has a Cash Flow Reinvestment Rate of 0.26x as of December 2024, reinvesting NT$41.15 Million (capex NT$9.09 Million plus investments NT$-32.06 Million) from operating cash flow of NT$156.75 Million. See Medigen Biotechnology (3176) FCF generation index to measure how efficiently the company converts operating cash flow to free cash.
Reinvestment Rate
Total Reinvested
Operating Cash Flow
Capital Expenditures
Medigen Biotechnology Cash Flow Reinvestment Rate (2003–2024)
Historical reinvestment intensity for Medigen Biotechnology across 5 annual periods. For the full cash flow conversion analysis, see 3176 operating cash flow.
Annual Cash Flow Reinvestment Rate for Medigen Biotechnology (2003–2024)
Year-by-year capital reinvestment analysis for Medigen Biotechnology. See 3176 free cash flow debt coverage to measure the company's free cash flow as a share of total liabilities.
| Year | Reinvestment Rate | Total Reinvested (TWD) | Operating CF | Capex | YoY Change |
|---|---|---|---|---|---|
| 2024 | 26.90x | NT$1.02 Billion | NT$37.92 Million | NT$58.68 Million | ▲ +1259.2% |
| 2021 | 1.98x | NT$1.02 Billion | NT$517.45 Million | NT$144.55 Million | ▼ -45.0% |
| 2015 | 3.60x | NT$1.06 Billion | NT$294.18 Million | NT$515.25 Million | ▲ +8952.2% |
| 2005 | 0.04x | NT$3.21 Million | NT$80.72 Million | NT$3.21 Million | ▲ +347.7% |
| 2003 | 0.01x | NT$3.96 Million | NT$445.46 Million | NT$3.96 Million | — |